VIR BIOTECHNOLOGY INC (VIR)

US92764N1028 - Common Stock

7.34  -0.03 (-0.41%)

After market: 7.39 +0.05 (+0.68%)

Fundamental Rating

4

Overall VIR gets a fundamental rating of 4 out of 10. We evaluated VIR against 568 industry peers in the Biotechnology industry. VIR has a great financial health rating, but its profitability evaluates not so good. VIR is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year VIR has reported negative net income.
VIR had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: VIR reported negative net income in multiple years.
In the past 5 years VIR reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -35.60%, VIR is in the better half of the industry, outperforming 62.48% of the companies in the same industry.
VIR has a Return On Equity of -42.99%. This is in the better half of the industry: VIR outperforms 71.15% of its industry peers.
Industry RankSector Rank
ROA -35.6%
ROE -42.99%
ROIC N/A
ROA(3y)4.47%
ROA(5y)-10.64%
ROE(3y)7.69%
ROE(5y)-11.96%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of VIR (98.78%) is better than 98.23% of its industry peers.
The Profit Margin and Operating Margin are not available for VIR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

7

2. Health

2.1 Basic Checks

VIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
VIR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VIR has been increased compared to 5 years ago.
There is no outstanding debt for VIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of 1.28, we must say that VIR is in the distress zone and has some risk of bankruptcy.
VIR has a Altman-Z score of 1.28. This is in the better half of the industry: VIR outperforms 67.61% of its industry peers.
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.28
ROIC/WACCN/A
WACC11.91%

2.3 Liquidity

VIR has a Current Ratio of 8.94. This indicates that VIR is financially healthy and has no problem in meeting its short term obligations.
VIR has a Current ratio of 8.94. This is in the better half of the industry: VIR outperforms 77.17% of its industry peers.
VIR has a Quick Ratio of 8.94. This indicates that VIR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.94, VIR is in the better half of the industry, outperforming 77.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.94
Quick Ratio 8.94

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.69% over the past year.
Looking at the last year, VIR shows a very negative growth in Revenue. The Revenue has decreased by -33.82% in the last year.
The Revenue has been growing by 51.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.87%
Revenue 1Y (TTM)-33.82%
Revenue growth 3Y4.1%
Revenue growth 5Y51.78%
Sales Q2Q%-9.81%

3.2 Future

VIR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.30% yearly.
VIR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.82% yearly.
EPS Next Y13.59%
EPS Next 2Y7.81%
EPS Next 3Y5.01%
EPS Next 5Y7.3%
Revenue Next Year-4.21%
Revenue Next 2Y-37.81%
Revenue Next 3Y-21.54%
Revenue Next 5Y32.82%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VIR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.81%
EPS Next 3Y5.01%

More info and screens

0

5. Dividend

5.1 Amount

VIR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIR BIOTECHNOLOGY INC

NASDAQ:VIR (12/20/2024, 8:00:01 PM)

After market: 7.39 +0.05 (+0.68%)

7.34

-0.03 (-0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/amc
Earnings (Next)02-20 2025-02-20/amc
Inst Owners73.46%
Inst Owner Change-0.96%
Ins Owners2.59%
Ins Owner Change3.84%
Market Cap1.01B
Analysts76.92
Price Target30.09 (309.95%)
Short Float %5.26%
Short Ratio4.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.76%
Min EPS beat(2)-46.72%
Max EPS beat(2)-12.81%
EPS beat(4)2
Avg EPS beat(4)2.7%
Min EPS beat(4)-46.72%
Max EPS beat(4)54.8%
EPS beat(8)2
Avg EPS beat(8)-14.9%
EPS beat(12)5
Avg EPS beat(12)-2.89%
EPS beat(16)7
Avg EPS beat(16)192.59%
Revenue beat(2)0
Avg Revenue beat(2)-58.31%
Min Revenue beat(2)-59.38%
Max Revenue beat(2)-57.23%
Revenue beat(4)2
Avg Revenue beat(4)74.18%
Min Revenue beat(4)-59.38%
Max Revenue beat(4)376.59%
Revenue beat(8)3
Avg Revenue beat(8)13.93%
Revenue beat(12)6
Avg Revenue beat(12)15.34%
Revenue beat(16)7
Avg Revenue beat(16)6.41%
PT rev (1m)-12.87%
PT rev (3m)-12.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.46%
EPS NY rev (1m)-1.03%
EPS NY rev (3m)-15.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-24.1%
Revenue NY rev (1m)9.5%
Revenue NY rev (3m)6.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.86
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-3.92
EYN/A
EPS(NY)-3.85
Fwd EYN/A
FCF(TTM)-3.44
FCFYN/A
OCF(TTM)-3.39
OCFYN/A
SpS0.57
BVpS9.01
TBVpS8.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.6%
ROE -42.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.78%
FCFM N/A
ROA(3y)4.47%
ROA(5y)-10.64%
ROE(3y)7.69%
ROE(5y)-11.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.11%
Cap/Sales 8.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.94
Quick Ratio 8.94
Altman-Z 1.28
F-Score3
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)495.59%
Cap/Depr(5y)360.98%
Cap/Sales(3y)10.41%
Cap/Sales(5y)29.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.87%
EPS Next Y13.59%
EPS Next 2Y7.81%
EPS Next 3Y5.01%
EPS Next 5Y7.3%
Revenue 1Y (TTM)-33.82%
Revenue growth 3Y4.1%
Revenue growth 5Y51.78%
Sales Q2Q%-9.81%
Revenue Next Year-4.21%
Revenue Next 2Y-37.81%
Revenue Next 3Y-21.54%
Revenue Next 5Y32.82%
EBIT growth 1Y18.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.26%
EBIT Next 3Y14.29%
EBIT Next 5Y12.04%
FCF growth 1Y-130.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-128.52%
OCF growth 3YN/A
OCF growth 5YN/A